Rachel S Midgley

Summary

Affiliation: Cancer Research UK
Country: UK

Publications

  1. ncbi request reprint Immunotherapy for colorectal cancer
    Rachel S Midgley
    Department of Health Clinician Scientist and Specialist Registrar Medical Oncology, Cancer Research UK, Churchill Hospital, Oxford
    Expert Rev Anticancer Ther 3:63-78. 2003
  2. ncbi request reprint Bevacizumab--current status and future directions
    Rachel Midgley
    Department of Clinical Pharmacology and Cancer Therapeutics, Racliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
    Ann Oncol 16:999-1004. 2005
  3. ncbi request reprint A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan
    R S Midgley
    Department of Clinical Pharmacology, University of Oxford, Oxford, UK
    Ann Oncol 18:2025-9. 2007
  4. doi request reprint Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial
    Rachel S Midgley
    Department of Clinical Pharmacology, University of Oxford, Headington, Oxford, United Kingdom
    J Clin Oncol 28:4575-80. 2010
  5. doi request reprint Evolution of nonsurgical therapy for colorectal cancer
    Rachel S Midgley
    Department of Clinical Pharmacology, University of Oxford, Old Road Campus Research Building, Old Road, off Roosevelt Drive, Headington, Oxford, UK
    Nat Clin Pract Gastroenterol Hepatol 6:108-20. 2009
  6. doi request reprint The emergence of 'omics for the management of colorectal cancer
    Rachel S Midgley
    Department of Clinical Pharmacology, University of Oxford, Oxford, UK
    Curr Opin Oncol 23:410-4. 2011
  7. ncbi request reprint Ras as a target in cancer therapy
    Rachel S Midgley
    CRC Institute for Cancer Studies, University of Birmingham, Birmingham, B15 2TT, Edgbaston, UK
    Crit Rev Oncol Hematol 44:109-20. 2002

Detail Information

Publications7

  1. ncbi request reprint Immunotherapy for colorectal cancer
    Rachel S Midgley
    Department of Health Clinician Scientist and Specialist Registrar Medical Oncology, Cancer Research UK, Churchill Hospital, Oxford
    Expert Rev Anticancer Ther 3:63-78. 2003
    ....
  2. ncbi request reprint Bevacizumab--current status and future directions
    Rachel Midgley
    Department of Clinical Pharmacology and Cancer Therapeutics, Racliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
    Ann Oncol 16:999-1004. 2005
    ..Questions still surround optimal dosing and the appropriate selection of patients who are most likely to benefit. Future trials will address these questions and provide further translational insights...
  3. ncbi request reprint A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan
    R S Midgley
    Department of Clinical Pharmacology, University of Oxford, Oxford, UK
    Ann Oncol 18:2025-9. 2007
    ....
  4. doi request reprint Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial
    Rachel S Midgley
    Department of Clinical Pharmacology, University of Oxford, Headington, Oxford, United Kingdom
    J Clin Oncol 28:4575-80. 2010
    ..The purpose of this study was to test whether the COX-2 inhibitor rofecoxib could reduce recurrence and improve survival when administered in the adjuvant setting of colorectal cancer (CRC)...
  5. doi request reprint Evolution of nonsurgical therapy for colorectal cancer
    Rachel S Midgley
    Department of Clinical Pharmacology, University of Oxford, Old Road Campus Research Building, Old Road, off Roosevelt Drive, Headington, Oxford, UK
    Nat Clin Pract Gastroenterol Hepatol 6:108-20. 2009
    ....
  6. doi request reprint The emergence of 'omics for the management of colorectal cancer
    Rachel S Midgley
    Department of Clinical Pharmacology, University of Oxford, Oxford, UK
    Curr Opin Oncol 23:410-4. 2011
    ..However, most studies have been underpowered and demonstrate elements of a statistical 'fishing exercise', that is the carrying out of a huge number of analyses to find a hint of importance for a particular marker...
  7. ncbi request reprint Ras as a target in cancer therapy
    Rachel S Midgley
    CRC Institute for Cancer Studies, University of Birmingham, Birmingham, B15 2TT, Edgbaston, UK
    Crit Rev Oncol Hematol 44:109-20. 2002
    ..Though their clinical evaluation is still in infancy, these two modes of ras targeting represent rational therapeutic strategies that can undergo mechanistic evaluation in the clinic...